Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

2(29%)

Results Posted

200%(4 trials)

Terminated

2(29%)

Phase Distribution

Ph phase_2

71%

Ph phase_1

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Terminated(3)

Detailed Status

Active, not recruiting2

Completed2

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (28.6%)

Phase 25 (71.4%)

Trials by Status

active_not_recruiting229%

withdrawn114%

completed229%

terminated229%

Recent Activity

2 active trials

Showing 5 of 7

terminatedphase_2

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

NCT03506373

active_not_recruitingphase_2

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427

active_not_recruitingphase_2

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

NCT02152995

completedphase_1

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

NCT03290937

terminatedphase_2

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

NCT03601507

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03506373Phase 2

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated

NCT03872427Phase 2

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Active Not Recruiting

NCT02152995Phase 2

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Active Not Recruiting

NCT03290937Phase 1

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Completed

NCT03601507Phase 2

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Terminated

NCT03592407Phase 2

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Withdrawn

NCT03291938Phase 1

IACS-010759 in Advanced Cancers

Completed

All 7 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 7